Polymer Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Polymer Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,104	Closed	-$966K	–	660
2026 Q1	$966K	Sell	17,104 -7,179	-30%	-$419K	0.1%	218
2025 Q4	$1.44M	Buy	24,283 +2,510	+12%	+$137K	0.15%	152
2025 Q3	$1.18M	Buy	21,773 +13,759	+172%	+$787K	0.12%	151
2025 Q2	$441K	Buy	+8,014	New	+$472K	0.05%	291

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Polymer Capital Management's BMRN Position: Q2 2026 in Review

Polymer Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 17,104 shares — an estimated $966K sold.

Polymer Capital Management first reported a position in BMRN in Q2 2025 and held it in 4 quarters. The position peaked at $1.44M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Polymer Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Polymer Capital Management sold 17,104 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $966K.
Polymer Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Polymer Capital Management's BioMarin Pharmaceuticals position peaked at $1.44M in Q4 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.